SalvaRx Group plc Delay in iOx development programme (4740V)

TIDMSALV

RNS Number : 4740V

SalvaRx Group plc

23 July 2018

SalvaRx Group plc

("SalvaRx" or the "Company")

Delay to iOx development programme

SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, announces that its 57% owned subsidiary, iOx Therapeutics Limited ("iOx"), has experienced a significant delay in manufacturing its lead drug candidate IMM60.

Due to quality failures in the manufacturing process that led to a batch failure, iOx is revising its timeline to dosing its first human in clinical trials. The company is confident that its process is robust and that it will move the programme forward in due course. Release of the product required for the initiation of human dosing is now likely to be in late 2019.

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

-Ends-

 
 SalvaRx Group plc 
 Ian Walters (Chief Executive)                Tel: +1 203 441 5451 
 
 Northland Capital Partners Limited           Tel: +44 (0) 20 3861 
  Nominated Adviser and Broker                                6625 
 Matthew Johnson / Edward Hutton (Corporate 
  Finance) 
 Vadim Alexandre (Corporate Broking) 
 
 
 Peterhouse Corporate Finance Limited   Tel: +44 (0) 20 7469 
  Joint Broker                                          0932 
  Lucy Williams / Duncan Vasey

For more information please visit: www.salvarx.io

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCUOAURWSABUAR

(END) Dow Jones Newswires

July 23, 2018 08:17 ET (12:17 GMT)

Salvarx (LSE:SALV)
Historical Stock Chart
From Apr 2024 to May 2024